Healthcare Market Segmentation
Healthcare By Disease Indication (USD Billion, 2025-2035)
- Brain Metastasis
- Cancer
- Arteriovenous Malformation
- Trigeminal Neuralgia
- Others
Healthcare By Anatomy (USD Billion, 2025-2035)
- Head
- Neck
- Others
Request Free Sample
×
Gamma Knife Market
ID: MRFR/HC/17643-HCR
128 Pages
Last Updated: April 06, 2026
Global Gamma Knife Market Research Report Information By Disease Indication (Brain Metastasis, Cancer, Arteriovenous Malformation, Trigeminal Neuralgia, Others), By Anatomy (Head, Neck, Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035
- 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
- 1.1 EXECUTIVE SUMMARY
- 1.1.1 Market Overview
- 1.1.2 Key Findings
- 1.1.3 Market Segmentation
- 1.1.4 Competitive Landscape
- 1.1.5 Challenges and Opportunities
- 1.1.6 Future Outlook
- 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
- 2.1 MARKET INTRODUCTION
- 2.1.1 Definition
- 2.1.2 Scope of the study
- 2.1.2.1 Research Objective
- 2.1.2.2 Assumption
- 2.1.2.3 Limitations
- 2.2 RESEARCH METHODOLOGY
- 2.2.1 Overview
- 2.2.2 Data Mining
- 2.2.3 Secondary Research
- 2.2.4 Primary Research
- 2.2.4.1 Primary Interviews and Information Gathering Process
- 2.2.4.2 Breakdown of Primary Respondents
- 2.2.5 Forecasting Model
- 2.2.6 Market Size Estimation
- 2.2.6.1 Bottom-Up Approach
- 2.2.6.2 Top-Down Approach
- 2.2.7 Data Triangulation
- 2.2.8 Validation
- 3 SECTION III: QUALITATIVE ANALYSIS
- 3.1 MARKET DYNAMICS
- 3.1.1 Overview
- 3.1.2 Drivers
- 3.1.3 Restraints
- 3.1.4 Opportunities
- 3.2 MARKET FACTOR ANALYSIS
- 3.2.1 Value chain Analysis
- 3.2.2 Porter's Five Forces Analysis
- 3.2.2.1 Bargaining Power of Suppliers
- 3.2.2.2 Bargaining Power of Buyers
- 3.2.2.3 Threat of New Entrants
- 3.2.2.4 Threat of Substitutes
- 3.2.2.5 Intensity of Rivalry
- 3.2.3 COVID-19 Impact Analysis
- 3.2.3.1 Market Impact Analysis
- 3.2.3.2 Regional Impact
- 3.2.3.3 Opportunity and Threat Analysis
- 4 SECTION IV: QUANTITATIVE ANALYSIS
- 4.1 Healthcare, BY Disease Indication (USD Billion)
- 4.1.1 Brain Metastasis
- 4.1.2 Cancer
- 4.1.3 Arteriovenous Malformation
- 4.1.4 Trigeminal Neuralgia
- 4.1.5 Others
- 4.2 Healthcare, BY Anatomy (USD Billion)
- 4.2.1 Head
- 4.2.2 Neck
- 4.2.3 Others
- 4.3 Healthcare, BY Region (USD Billion)
- 4.3.1 North America
- 4.3.1.1 US
- 4.3.1.2 Canada
- 4.3.2 Europe
- 4.3.2.1 Germany
- 4.3.2.2 UK
- 4.3.2.3 France
- 4.3.2.4 Russia
- 4.3.2.5 Italy
- 4.3.2.6 Spain
- 4.3.2.7 Rest of Europe
- 4.3.3 APAC
- 4.3.3.1 China
- 4.3.3.2 India
- 4.3.3.3 Japan
- 4.3.3.4 South Korea
- 4.3.3.5 Malaysia
- 4.3.3.6 Thailand
- 4.3.3.7 Indonesia
- 4.3.3.8 Rest of APAC
- 4.3.4 South America
- 4.3.4.1 Brazil
- 4.3.4.2 Mexico
- 4.3.4.3 Argentina
- 4.3.4.4 Rest of South America
- 4.3.5 MEA
- 4.3.5.1 GCC Countries
- 4.3.5.2 South Africa
- 4.3.5.3 Rest of MEA
- 5 SECTION V: COMPETITIVE ANALYSIS
- 5.1 Competitive Landscape
- 5.1.1 Overview
- 5.1.2 Competitive Analysis
- 5.1.3 Market share Analysis
- 5.1.4 Major Growth Strategy in the Healthcare
- 5.1.5 Competitive Benchmarking
- 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
- 5.1.7 Key developments and growth strategies
- 5.1.7.1 New Product Launch/Service Deployment
- 5.1.7.2 Merger & Acquisitions
- 5.1.7.3 Joint Ventures
- 5.1.8 Major Players Financial Matrix
- 5.1.8.1 Sales and Operating Income
- 5.1.8.2 Major Players R&D Expenditure. 2023
- 5.2 Company Profiles
- 5.2.1 Elekta AB (SE)
- 5.2.1.1 Financial Overview
- 5.2.1.2 Products Offered
- 5.2.1.3 Key Developments
- 5.2.1.4 SWOT Analysis
- 5.2.1.5 Key Strategies
- 5.2.2 Accuray Incorporated (US)
- 5.2.2.1 Financial Overview
- 5.2.2.2 Products Offered
- 5.2.2.3 Key Developments
- 5.2.2.4 SWOT Analysis
- 5.2.2.5 Key Strategies
- 5.2.3 Varian Medical Systems (US)
- 5.2.3.1 Financial Overview
- 5.2.3.2 Products Offered
- 5.2.3.3 Key Developments
- 5.2.3.4 SWOT Analysis
- 5.2.3.5 Key Strategies
- 5.2.4 Brainlab AG (DE)
- 5.2.4.1 Financial Overview
- 5.2.4.2 Products Offered
- 5.2.4.3 Key Developments
- 5.2.4.4 SWOT Analysis
- 5.2.4.5 Key Strategies
- 5.2.5 MediTech (US)
- 5.2.5.1 Financial Overview
- 5.2.5.2 Products Offered
- 5.2.5.3 Key Developments
- 5.2.5.4 SWOT Analysis
- 5.2.5.5 Key Strategies
- 5.2.6 Shenzhen Huikang Medical (CN)
- 5.2.6.1 Financial Overview
- 5.2.6.2 Products Offered
- 5.2.6.3 Key Developments
- 5.2.6.4 SWOT Analysis
- 5.2.6.5 Key Strategies
- 5.2.7 Nanjing Jinling Medical (CN)
- 5.2.7.1 Financial Overview
- 5.2.7.2 Products Offered
- 5.2.7.3 Key Developments
- 5.2.7.4 SWOT Analysis
- 5.2.7.5 Key Strategies
- 5.2.8 Stereotactic Radiosurgery (US)
- 5.2.8.1 Financial Overview
- 5.2.8.2 Products Offered
- 5.2.8.3 Key Developments
- 5.2.8.4 SWOT Analysis
- 5.2.8.5 Key Strategies
- 5.3 Appendix
- 5.3.1 References
- 5.3.2 Related Reports
- 6 LIST OF FIGURES
- 6.1 MARKET SYNOPSIS
- 6.2 NORTH AMERICA MARKET ANALYSIS
- 6.3 US MARKET ANALYSIS BY DISEASE INDICATION
- 6.4 US MARKET ANALYSIS BY ANATOMY
- 6.5 CANADA MARKET ANALYSIS BY DISEASE INDICATION
- 6.6 CANADA MARKET ANALYSIS BY ANATOMY
- 6.7 EUROPE MARKET ANALYSIS
- 6.8 GERMANY MARKET ANALYSIS BY DISEASE INDICATION
- 6.9 GERMANY MARKET ANALYSIS BY ANATOMY
- 6.10 UK MARKET ANALYSIS BY DISEASE INDICATION
- 6.11 UK MARKET ANALYSIS BY ANATOMY
- 6.12 FRANCE MARKET ANALYSIS BY DISEASE INDICATION
- 6.13 FRANCE MARKET ANALYSIS BY ANATOMY
- 6.14 RUSSIA MARKET ANALYSIS BY DISEASE INDICATION
- 6.15 RUSSIA MARKET ANALYSIS BY ANATOMY
- 6.16 ITALY MARKET ANALYSIS BY DISEASE INDICATION
- 6.17 ITALY MARKET ANALYSIS BY ANATOMY
- 6.18 SPAIN MARKET ANALYSIS BY DISEASE INDICATION
- 6.19 SPAIN MARKET ANALYSIS BY ANATOMY
- 6.20 REST OF EUROPE MARKET ANALYSIS BY DISEASE INDICATION
- 6.21 REST OF EUROPE MARKET ANALYSIS BY ANATOMY
- 6.22 APAC MARKET ANALYSIS
- 6.23 CHINA MARKET ANALYSIS BY DISEASE INDICATION
- 6.24 CHINA MARKET ANALYSIS BY ANATOMY
- 6.25 INDIA MARKET ANALYSIS BY DISEASE INDICATION
- 6.26 INDIA MARKET ANALYSIS BY ANATOMY
- 6.27 JAPAN MARKET ANALYSIS BY DISEASE INDICATION
- 6.28 JAPAN MARKET ANALYSIS BY ANATOMY
- 6.29 SOUTH KOREA MARKET ANALYSIS BY DISEASE INDICATION
- 6.30 SOUTH KOREA MARKET ANALYSIS BY ANATOMY
- 6.31 MALAYSIA MARKET ANALYSIS BY DISEASE INDICATION
- 6.32 MALAYSIA MARKET ANALYSIS BY ANATOMY
- 6.33 THAILAND MARKET ANALYSIS BY DISEASE INDICATION
- 6.34 THAILAND MARKET ANALYSIS BY ANATOMY
- 6.35 INDONESIA MARKET ANALYSIS BY DISEASE INDICATION
- 6.36 INDONESIA MARKET ANALYSIS BY ANATOMY
- 6.37 REST OF APAC MARKET ANALYSIS BY DISEASE INDICATION
- 6.38 REST OF APAC MARKET ANALYSIS BY ANATOMY
- 6.39 SOUTH AMERICA MARKET ANALYSIS
- 6.40 BRAZIL MARKET ANALYSIS BY DISEASE INDICATION
- 6.41 BRAZIL MARKET ANALYSIS BY ANATOMY
- 6.42 MEXICO MARKET ANALYSIS BY DISEASE INDICATION
- 6.43 MEXICO MARKET ANALYSIS BY ANATOMY
- 6.44 ARGENTINA MARKET ANALYSIS BY DISEASE INDICATION
- 6.45 ARGENTINA MARKET ANALYSIS BY ANATOMY
- 6.46 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE INDICATION
- 6.47 REST OF SOUTH AMERICA MARKET ANALYSIS BY ANATOMY
- 6.48 MEA MARKET ANALYSIS
- 6.49 GCC COUNTRIES MARKET ANALYSIS BY DISEASE INDICATION
- 6.50 GCC COUNTRIES MARKET ANALYSIS BY ANATOMY
- 6.51 SOUTH AFRICA MARKET ANALYSIS BY DISEASE INDICATION
- 6.52 SOUTH AFRICA MARKET ANALYSIS BY ANATOMY
- 6.53 REST OF MEA MARKET ANALYSIS BY DISEASE INDICATION
- 6.54 REST OF MEA MARKET ANALYSIS BY ANATOMY
- 6.55 KEY BUYING CRITERIA OF HEALTHCARE
- 6.56 RESEARCH PROCESS OF MRFR
- 6.57 DRO ANALYSIS OF HEALTHCARE
- 6.58 DRIVERS IMPACT ANALYSIS: HEALTHCARE
- 6.59 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
- 6.60 SUPPLY / VALUE CHAIN: HEALTHCARE
- 6.61 HEALTHCARE, BY DISEASE INDICATION, 2024 (% SHARE)
- 6.62 HEALTHCARE, BY DISEASE INDICATION, 2024 TO 2035 (USD Billion)
- 6.63 HEALTHCARE, BY ANATOMY, 2024 (% SHARE)
- 6.64 HEALTHCARE, BY ANATOMY, 2024 TO 2035 (USD Billion)
- 6.65 BENCHMARKING OF MAJOR COMPETITORS
- 7 LIST OF TABLES
- 7.1 LIST OF ASSUMPTIONS
- 7.1.1
- 7.2 North America MARKET SIZE ESTIMATES; FORECAST
- 7.2.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.2.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.3 US MARKET SIZE ESTIMATES; FORECAST
- 7.3.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.3.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
- 7.4.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.4.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
- 7.5.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.5.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
- 7.6.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.6.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.7 UK MARKET SIZE ESTIMATES; FORECAST
- 7.7.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.7.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.8 France MARKET SIZE ESTIMATES; FORECAST
- 7.8.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.8.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
- 7.9.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.9.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
- 7.10.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.10.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
- 7.11.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.11.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
- 7.12.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.12.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
- 7.13.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.13.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.14 China MARKET SIZE ESTIMATES; FORECAST
- 7.14.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.14.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.15 India MARKET SIZE ESTIMATES; FORECAST
- 7.15.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.15.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
- 7.16.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.16.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
- 7.17.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.17.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
- 7.18.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.18.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
- 7.19.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.19.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
- 7.20.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.20.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
- 7.21.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.21.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.22 South America MARKET SIZE ESTIMATES; FORECAST
- 7.22.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.22.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
- 7.23.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.23.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
- 7.24.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.24.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
- 7.25.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.25.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
- 7.26.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.26.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
- 7.27.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.27.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
- 7.28.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.28.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
- 7.29.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.29.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
- 7.30.1 BY DISEASE INDICATION, 2025-2035 (USD Billion)
- 7.30.2 BY ANATOMY, 2025-2035 (USD Billion)
- 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
- 7.31.1
- 7.32 ACQUISITION/PARTNERSHIP
- 7.32.1
Customer Stories
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
Noah Malgeri
Co-Founder
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
Joseph Aguayo
Sales Operations & Pricing Manager
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
Peter Groot koerkamp
Account and Business Manager
“Thank you, this will be very helpful for OQS.”
La Terria Dodd
Program Support Specialist
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
Younghwan Choi
Senior Retail Manager
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Mark Irwin
Management Consultant
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
Akif Moroglu
Strategy & Business Development Director
Case Study